Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales

LEN/DEX is a cost effective oncology therapy from the perspective of the NHS for MM patients with one prior treatment. </AbstractSection> Copyright Springer-Verlag 2013

MoreLess

Year of publication:	2013
Authors:	Brown, Ruth ; Stern, Sean ; Dhanasiri, Sujith ; Schey, Steve
Published in:	The European Journal of Health Economics. - Springer. - Vol. 14.2013, 3, p. 507-514
Publisher:	Springer
Subject:	Lenalidomide \| Multiple myeloma \| Cost effectiveness \| Dexamethasone \| Patient access scheme

Online Resource

Check full text access |

More access options

Check Google Scholar

In German libraries (KVK)

I need help

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10010993909